Results 81 to 90 of about 6,081 (225)
. Background:. Previous studies on whether or not levosimendan improved the prognosis of patients with sepsis and septic shock have been inconsistent. We aimed to provide an updated analysis of the therapeutic value of levosimendan in adult patients with
Fang Feng +6 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 4, Page 3200-3208, August 2025.
Massimo Mapelli +9 more
wiley +1 more source
Cervical cancer presents a significant challenge to the global health of women. Despite substantial advances in human papillomavirus (HPV)-related cervical cancer vaccines, non-HPV-related cervical cancer is still waiting novel therapeutic options.
Zsuzsanna Schelz +4 more
doaj +1 more source
Ugur Koca, Burcu Tanay Demirdöven
openaire +2 more sources
The effect of the calcium sensitizer levosimendan on the performance and the response to pacing of stunned myocardium in anaesthetized pigs [PDF]
H. Schad +6 more
openalex +1 more source
Background The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP).
Matsumoto Shuhei +6 more
doaj +1 more source
Levosimendan For Post-Partum Cardiomyopathy
To describe the use of levosimendan, a novel inotropic agent, for the treatment of post-partum cardiomyopathy (PPCMO).The authors present the second recorded use of levosimendan for a woman with PPCMO.Levosimendan improved cardiac performance which was associated with symptomatic relief and echocardiographic improvement in ventricular function.
H D, Nguyen, B, McKeown
openaire +2 more sources
Binding of Levosimendan, a Calcium Sensitizer, to Cardiac Troponin C [PDF]
Tia Sorsa +11 more
openalex +1 more source
Levosimendan in acute heart failure
Numerous adverse effects and an increased mortality are the reasons why many clinicians are often unsuccessful with the inotropic agents presently in use. New therapeutic agents have been developed in the last few years to assist the clinician in the stabilization, support and treatment of cardiovascular disease.One of the newest groups of inotropic ...
HUSEDZINOVIC, INO +2 more
openaire +4 more sources
Intravenous levosimendan treatment is cost‐effective compared with dobutamine in severe low‐output heart failure: an analysis based on the international LIDO trial [PDF]
John G.F. Cleland +4 more
openalex +1 more source

